
	Three Months Ended				Nine Months Ended
	October 1, 2021		October 2, 2020		October 1, 2021		October 2, 2020
	(In thousands)
Net sales:
Fabrication Technology	$	605,968	$	491,497	$	1,803,900	$	1,431,401
Medical Technology	359,923		314,434		1,027,130		811,246
	$	965,891	$	805,931	$	2,831,030	$	2,242,647
Segment operating income (loss)(1):
Fabrication Technology	$	90,604	$	63,058	$	267,306	$	175,703
Medical Technology	10,845		22,869		31,254		5,877
Corporate and other	(29,100)		(15,079)		(75,765)		(44,730)
	$	72,349	$	70,848	$	222,795	$	136,850

(1) Following is a reconciliation of Income (loss) from continuing operations before income taxes to segment operating income:


	Three Months Ended				Nine Months Ended
	October 1, 2021		October 2, 2020		October 1, 2021		October 2, 2020
	(In thousands)
Income from continuing operations before income taxes	$	50,450	$	36,364	$	125,571	$	25,200

Pension settlement gain	—		—		(11,208)		—
Interest expense, net	13,540		25,567		57,005		78,647
Debt extinguishment charges	—		—		29,870		—
Restructuring and other related charges(1)	6,457		6,328		15,983		28,514
MDR and other costs(2)	1,902		2,589		5,574		4,489
Segment operating income	$	72,349	$	70,848	$	222,795	$	136,850

(1) Restructuring and other related charges includes $2.2 million and $4.9 million of expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended October 2, 2020, respectively.

(2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on the Company’s Condensed Consolidated Statements of Operations for all periods presented.